drugset / Trial / NCT01916304

Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation

NCT01916304

Phase 2 Completed 101 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate the effect of switching participants taking levothyroxine to a new sodium formulation.

Timeline

Start
2013-07
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Levothyroxine Other / unclassified 25 ug Oral
Subject Levothyroxine Other / unclassified 225 ug Oral

Indications